Cardiometabolic risk factors and renin-angiotensin system polymorphisms in young individuals with various metabolic phenotypes

Background. The increased prevalence of obesity and associated cardiometabolic diseases attract attention worldwide. Renin-angiotensin system can link obesity and cardiovascular and metabolic diseases.

Objective. To access a comprehensive assessment of cardiometabolic risk factors and gene polymorphisms of the renin-angiotensin system in metabolic phenotypes among young individuals.

Design and methods. The sample consisted of 251 individuals, who were divided into four groups: group 1 — metabolically healthy individuals with normal body mass index (BMI) (n = 62); group 2 — metabolically unhealthy individuals with normal BMI (n = 57); group 3 — metabolically healthy overweight/obese individuals (n = 16); group 4— metabolically unhealthy overweight/ obese individuals (n = 116). All participants answered a questionnaire designed for this study. Anthropometric, clinical and biochemical parameters were assessed. The following polymorphisms were evaluated:, A1166C polymorphism of the angiotensin II type 1 receptor gene (rs5186), M235T polymorphism of the angiotensinogen gene (rs699), T174M polymorphism of the angiotensinogen gene (rs4762), I/D polymorphism of the angiotensinconverting enzyme gene (rs4340).

Results. In young individuals with metabolically unhealthy overweight/ obesity, a higher frequency of coexistent abdominal obesity and hypertension was found in combination with a higher frequency of the allele T of AGT 235M/T. The greater differences in carbohydrate and lipid metabolism in combination with a higher serum levels of leptin and low serum concentrations of adiponectin were also found in young individuals with metabolically unhealthy overweight/obesity.

1. Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33(7):673–689. doi:10.1007/s40273-014-0243-x

2. World Health Organization (WHO). Obesity and overweight. Geneve: WHO; 2021. Available from: https://www.who.int/newsroom/fact-sheets/detail/obesity-and-overweight [cited 2022 Jan 31].

3. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113(6):898–918. doi:10.1161/CIRCULATIONAHA.106.171016

4. Chulkov VS, Lenets EA, Chulkov VS, Gavrilova ES, Minina EE, Zhdanova OV. Gender characteristics of the pathogenesis, prevention and treatment of metabolic syndrome. Arterial’naya Gipertenziya = Arterial Hypertension. 2020;26(4):371–382. doi:10.18705/1607-419X‑2020-26-4-371-382. In Russian.

5. Cabandugama PK, Gardner MJ, Sowers JR. The reninangiotensin-aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. Med Clin North Am. 2017; 101(1):129–137. doi:10.1016/j.mcna.2016.08.009

6. Lastra G, Sowers JR. Obesity and cardiovascular disease: role of adipose tissue, inflammation, and the reninangiotensinaldosterone system. Horm Mol Biol Clin Investig. 2013;15(2):49–57. doi:10.1515/hmbci‑2013-0025

7. Thethi T, Kamiyama M, Kobori H. The link between the renin-angiotensin aldosterone system and renal injury in obesity and the metabolic syndrome. Curr Hypertens Rep. 2012;14(2):160–169. doi:10.1007/s11906-012-0245-z

8. Pinheiro TA, Barcala-Jorge AS, Andrade JMO, Pinheiro TA, Ferreira ECN, Crespo TS et al. Obesity and malnutrition similarly alter the renin-angiotensin system and inflammation in mice and human adipose. J Nutr Biochem. 2017;48:74–82. doi:10.1016/j.jnutbio.2017.06.008

9. Szczepanska-Sadowska E, Rossi NF. Editorial: new trends in the renin-angiotensin-aldosterone system in cardiovascular disease. Front Pharmacol. 2021;12:790439. doi:10.3389/fphar.2021.790439

10. Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015;116(6):960–975. doi:10.1161/CIRCRESAHA.116.303587

11. Wu CK, Lee JK, Lin LY, Huang YT, Hwang JJ, Lin CL et al. Renin- angiotensin system genes polymorphisms and long-term prognosis in Taiwanese patients with hypertension and coronary artery disease. Acta Cardiol Sin. 2013;29(1):28–36.

12. Ji LD, Li JY, Yao BB, Cai XB, Shen QJ, Xu J. Are genetic polymorphisms in the renin-angiotensin-aldosterone system associated with essential hypertension? Evidence from genomewide association studies. J Hum Hypertens. 2017;31(11):695–698. doi:10.1038/jhh.2017.29

13. Lelis DF, Pereira AC, Krieger JE, Mill JG, Santos SHS, Baldo MP. Polymorphisms of the renin-angiotensin system are not associated with overweight and obesity in a general adult population. Arch Endocrinol Metab. 2019;63(4):402–410. doi:10.20945/2359-3997000000155

14. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat of atherosclerosis Russian recommendations VII revision. J Atheroscler Dyslipidem. 2020;1(38):7–42. doi:10.34687/2219-8202.JAD.2020.01.0002. In Russian.

15. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012;33(16):2088–2097. doi:10.1093/eurheartj/ehs075

16. Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2012;302(6): H1219–30. doi:10.1152/ajpheart.00796.2011

17. Pacholczyk M, Ferenc T, Kowalski J, Adamczyk P, Chojnowski J, Ponikowska I. Association of angiotensin-converting enzyme and angiotensin II type I receptor gene polymorphisms with extreme obesity in Polish individuals. DNA Cell Biol. 2013;32(8):435–442. doi:10.1089/dna.2013.2014

18. Takakura Y, Yoshida T, Yoshioka K, Umekawa T, KogureA, Toda H et al. Angiotensinogen gene polymorphism (Met235Thr) influences visceral obesity and insulin resistance in obese Japanese women. Metabolism. 2006;55(6):819–824. doi:10.1016/j.metabol.2006.02.008

19. Pan YH, Wang M, Huang YM, Wang YH, Chen YL, Geng LJ et al. ACE gene I/D polymorphism and obesity in 1,574 patients with type 2 diabetes mellitus. Dis Markers. 2016;2016:7420540. doi:10.1155/2016/7420540

20. Motawi TK, Shaker OG, Shahin NN, Ahmed NM. Angiotensinconverting enzyme insertion/deletion polymorphism association with obesity and some related disorders in Egyptian females: a case-control observational study. Nutr Metab (Lond). 2016;13:68. doi:10.1186/s12986-016-0127-5